Positivity of SARS-CoV-2 nucleic acid and antibody of different biological specimens from COVID-19 cases in Dongguan city – a comparative analysis
-
摘要:
目的 探讨新冠肺炎患者不同生物标本核酸和抗体的结果变化特征。 方法 于2020年1月23日 — 2020年10月9日,收集广东省东莞市101例新冠肺炎(COVID-19)确诊病例和35例无症状感染者各种生物样品,进行RT-PCR核酸检测和IgM、IgG抗体检测,并分析其结果。 结果 新冠病毒(SARS-CoV-2)核酸阳性持续中位时间为7.00 d(0.00~27.00 d)。在COVID-19确诊患者发病0~7 d内,咽拭子核酸检测样本阳性率为48.21 %(121/251),肛拭子核酸检测阳性率为36.00 %(9/25),鼻咽拭子核酸检测阳性率为31.82 %(7/22)。尿液样本在整个病程阶段均未检出新冠病毒样本核酸阳性。无症状感染者的咽拭子、肛拭子及鼻咽拭子核酸检测均有检出阳性,痰、粪便样本核酸检测未检出阳性。 结论 随着新冠肺炎病程的不断推进,咽拭子、肛拭子及鼻咽拭子核酸阳性检出率随之降低,而血清中IgG抗体阳性检出率随之升高。 -
关键词:
- 新冠肺炎 /
- SARS-CoV-2 /
- 生物样本
Abstract:Objective To investigate positive rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid and antibody of different biological samples from diagnosed coronavirus disease 2019 (COVID-19) patients. Methods A variety of biological samples were collected from 101 confirmed COVID-19 cases and 35 asymptomatic infected persons in Dongguan city, Guangdong province from January 23 to October 9, 2020. SARS-CoV-2 nucleic acid was detected with real-time fluorescence quantitative reverse transcriptase polymerase chain reaction (RT-PCR); serum immunoglobulin M (IgM) and IgG antibodies against SARS-CoV-2 were measured with colloidal gold method. The detection results were analyzed statistically. Results The median duration of persistent positivity of SARS-CoV-2 nucleic acid the was 7.00 days (interquartile range: 0.00 – 27.00 days) for all the patients. Within 0 – 7 days after the onset of COVID-19, the positive rates were 48.21% (121/251), 36.00% (9/25), and 31.82% (7/22) for pharyngeal, anal, and nasopharyngeal swab specimens, respectively. No SARS-CoV-2 nucleic acid positive urine samples were detected during whole course of the disease for all the patients. SARS-CoV-2 nucleic acid positive pharyngeal, anal, and nasopharyngeal swab specimens were detected but no positive sputum and feces samples were detected among the asymptomatic patients. Conclusion With the progress of disease, the positive rate of SARS-CoV-2 nucleic acid decreases for pharyngeal, anal, and nasopharyngeal swab specimens from COVID-19 patients but that of serum IgG antibody against SARS-CoV-2 increases. -
Key words:
- COVID-19 /
- SARS-CoV-2 /
- biological specimen
-
表 1 新冠病毒核酸检测阳性时间
项目 新冠病毒核酸检测时间(d) 从发病到 第1次核酸检测时间(d) 1.00 (– 1.00~2.00) 最后1次核酸检测时间(d) 45.00(32.00~57.00) 最后1次阳性结果的时间(d) 12.00(2.00~27.00) 新冠病毒核酸阳性持续时间(d) 7.00 (0.00~27.00) 注:数据以中位数(四分位数间距)表示。 表 2 确诊病例与无症状感染者不同样本中SARS-CoV-2 阳性率(%)
序号 类型 确诊病例(n = 101) 无症状感染者(n = 35) χ2 值 P 值 样本数 阳性数 阳性率(%) 样本数 阳性数 阳性率(%) 1 咽拭子 1022 216 21.14 212 36 16.98 1.864 0.172 2 鼻咽拭子 289 37 12.80 192 47 24.48 10.912 0.001 3 肛拭子 659 84 12.75 251 57 22.71 13.778 < 0.001 4 粪便 23 5 21.74 2 0 0.00 1.000 a 5 痰 3 1 33.33 1 0 0.00 1.000 a 6 阴道分泌物 3 1 33.33 7 宫颈分泌物 3 1 33.33 8 尿液 22 0 0.00 注:a 确切概率法。 表 3 确诊病例在不同病程及不同样本中SARS-CoV-2 核酸阳性情况(n = 101)
项目 0~7 d 8~14 d 15~21 d 22~28 d > 28 d 总份数 阳性数 阳性率 总份数 阳性数 阳性率 总份数 阳性数 阳性率 总份数 阳性数 阳性率 总份数 阳性数 阳性率 咽拭子 251 121 48.21 167 42 25.15 180 22 12.22 122 12 9.84 302 19 6.29 鼻咽拭子 22 7 31.82 44 3 6.82 59 7 11.86 50 7 14.00 114 13 11.40 肛拭子 25 9 36.00 52 15 28.85 95 11 11.58 131 18 13.74 356 31 8.71 粪便 2 1 50.00 21 4 19.05 痰 2 1 50.00 1 0 0.00 阴道分泌物 3 1 33.33 宫颈分泌物 3 1 33.33 尿液 5 0 0.00 4 0 0.00 8 0 0.00 3 0 0.00 2 0 0.00 血清 6 0 0.00 19 1 5.26 23 0 0.00 14 4 28.57 53 40 79.17 -
[1] 丁兆辉, 曾德传, 万丽玲, 等. 新冠肺炎并肝炎患者顽固性核酸阳性中医辨治体会[J]. 世界科学技术 – 中医药现代化, 2020, 22(12): 4340 – 4344. doi: 10.11842/wst.20200322001 [2] Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. New England Journal of Medicine, 2020, 382(8): 727 – 733. doi: 10.1056/NEJMoa2001017 [3] 王琛, 王旋. 新型冠状病毒感染的流行、医院感染及心理预防[J]. 全科护理, 2020, 18(3): 309 – 310. doi: 10.12104/j.issn.1674-4748.2020.03.016 [4] Wu JG, Liu JS, Li SJ, et al. Detection and analysis of nucleic acid in various biological samples of COVID - 19 patients[J]. Travel Medicine and Infectious Disease, 2020, 37: 101673. doi: 10.1016/j.tmaid.2020.101673 [5] Bwire GM, Majigo MV, Njiro BJ, et al. Detection profile of SARS - CoV - 2 using RT - PCR in different types of clinical specimens: a systematic review and meta - analysis[J]. Journal of Medical Virology, 2021, 93(2): 719 – 725. doi: 10.1002/jmv.26349 [6] 国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版): 国卫办医函[2020] 680号[EB/OL]. (2020 – 08 – 18)[2021 – 03 – 25]. http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml. [7] 卫生健康委员会. 关于印发新型冠状病毒肺炎防控方案(第七版)的通知: 联防联控机制综发〔2020〕229号[EB/OL]. (2020 – 09 – 15)[2021 – 09 – 23]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=318683cbfaee4191aee29cd774b19d8d. [8] 陈远彬, 范斐婷, 吴镇湖, 等. 新型冠状病毒肺炎与传染性非典型肺炎的发病机制、病理改变和影像学特征比较[J]. 暨南大学学报(自然科学与医学版), 2020, 41(5): 413 – 418. doi: 10.11778/j.jdxb.2020.05.005 [9] 吴燕子, 周强, 薛源, 等. 抗病毒药物治疗COVID-19的研究进展: 临床试验的系统综述[J]. 中国医院药学杂志, 2020, 40(20): 2184 – 2190. doi: 10.13286/j.1001-5213.2020.20.18 [10] Gao YJ, Ma XM, Bi JF, et al. Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history[J]. Virulence, 2020, 11(1): 1015 – 1023. doi: 10.1080/21505594.2020.1802870 [11] Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID - 19[J]. The Lancet Infectious Diseases, 2020, 20(4): 398 – 400. doi: 10.1016/S1473-3099(20)30141-9 [12] 吴建国, 罗建飞, 刘家盛, 等. 重型/危重型新型冠状病毒肺炎患者多种生物样本核酸检测结果分析[J]. 解放军医学院学报, 2020, 41(3): 205 – 207,211. doi: 10.3969/j.issn.2095-5227.2020.03.001 [13] Fan HW, Yu XQ, Fu XH, et al. Clinical implications of different specimen types for nucleic acid testing in two cases of COVID-19[J]. Journal of International Medical Research, 2020, 48(8): 300060520949067,doi: 10.1177/0300060520949067. [14] Lin CY, Xiang J, Yan MZ, et al. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS - Cov - 2) - infected pneumonia (COVID - 19)[J]. Clinical Chemistry and Laboratory Medicine, 2020, 58(7): 1089 – 1094. doi: 10.1515/cclm-2020-0187 [15] Han HQ, Luo QF, Mo F, et al. SARS - CoV - 2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID - 19 patients[J]. The Lancet Infectious Diseases, 2020, 20(6): 655 – 656. [16] 马志强, 王霖, 杜映荣, 等. COVID - 19不同临床标本核酸和抗体结果特征及与病程相关性研究[J]. 病毒学报, 2020, 36(6): 997 – 1003. doi: 10.13242/j.cnki.bingduxuebao.003776 [17] Aslan MM, Yuvacı HU, Köse O, et al. SARS-CoV-2 is not present in the vaginal fluid of pregnant women with COVID-19[J]. The Journal of Maternal-Fetal and Neonatal Medicine, 2020,doi: 10.1080/14767058.2020.1793318. [18] Qiu L, Liu X, Xiao M, et al. SARS - CoV - 2 is not detectable in the vaginal fluid of women with severe COVID - 19 infection[J]. Clinical Infectious Diseases, 2020, 71(15): 813 – 817. doi: 10.1093/cid/ciaa375 [19] Wang WL, Xu YL, Gao RQ, et al. Detection of SARS - CoV - 2 in different types of clinical specimens[J]. JAMA, 2020, 323(18): 1843 – 1844. [20] Brönimann S, Rebhan K, Lemberger U, et al. Secretion of severe acute respiratory syndrome coronavirus 2 in urine[J]. Current Opinion in Urology, 2020, 30(5): 735 – 739.
计量
- 文章访问数: 274
- HTML全文浏览量: 180
- PDF下载量: 27
- 被引次数: 0